Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Evofem Biosciences Inc (EVFM) USD0.001

Sell:$5.44 Buy:$5.45 Change: $0.01 (0.18%)
NASDAQ:0.73%
Market closed |  Prices as at close on 15 November 2019 | Switch to live prices |
Sell:$5.44
Buy:$5.45
Change: $0.01 (0.18%)
Market closed |  Prices as at close on 15 November 2019 | Switch to live prices |
Sell:$5.44
Buy:$5.45
Change: $0.01 (0.18%)
Market closed |  Prices as at close on 15 November 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Evofem Biosciences Inc, formerly Neothetics, Inc., is a clinical-stage specialty biopharmaceutical company. The Company develops products to address unmet needs in women's sexual and reproductive health. The Company’s product Amphora, is a Multipurpose Vaginal pH Regulator (MVP-R) designed to regulate vaginal pH to within the normal range of 3.5 to 4.5 even in the presence of semen. This maintains an acidic environment which is inhospitable to sperm as well as certain viral and bacterial pathogens associated with sexually transmitted infections. Amphora is used to prevent urogenital chlamydia and gonorrhea in women. The Company is in the second Phase III clinical trial of Amphora for prevention of pregnancy (AMP002). The Company is currently designing a Phase IIb trial for its second product candidate, a MVP-R to reduce the recurrence of bacterial vaginosis.

Contact details

Address:
12400 High Bluff Dr Ste 600
SAN DIEGO
92130-3077
United States
Telephone:
+1 (858) 5501900
Website:
https://www.evofem.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
EVFM
ISIN:
US30048L1044
Market cap:
$247.63 million
Shares in issue:
46.81 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Saundra Pelletier
    Chief Executive Officer
  • Justin File
    Chief Financial Officer
  • Maria Feldman
    Vice President, Clinical Operations, Regulatory Affairs and Quality Assurance
  • Alexander Fitzpatrick
    General Counsel, Secretary
  • Russell Barrans
    Chief Commercial Officer
  • Kelly Culwell
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.